Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

Clayton D. Harro, Yuk Ying Susana Pang, Richard B.S. Roden, Allan Hildesheim, Zhaohui Wang, Mary Jane Reynolds, T. Christopher Mast, Robin Robinson, Brian R. Murphy, Ruth A. Karron, Joakim Dillner, John T. Schiller, Douglas R. Lowy

Research output: Contribution to journalArticle

Abstract

Background: Studies in animal models have shown that systemic immunization with a papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral protein, can confer protection against subsequent experimental challenge with the homologous virus. Here we report results of a double-blind, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults. Methods: Volunteers were given intramuscular injections with placebo or with 10- or 50-μg doses of HPV16 L1 VLP vaccine given without adjuvant or with alum or MF59 as adjuvants at 0, 1, and 4 months. All vaccine recipients were monitored for clinical signs and symptoms for 7 days after each inoculation. Immune responses were measured by an HPV16 L1 VLP-based enzyme-linked immunosorbent assay (ELISA) and by an HPV16 pseudovirion neutralization assay. The antibody titers were given as the reciprocals of the highest dilution showing positive reactivity in each assay. All statistical tests were two-sided. Results: The prevaccination geometric mean ELISA titer for six seropositive individuals was 202 (range, 40-640). All vaccine formulations were well tolerated, and all subjects receiving vaccine seroconverted. Serum antibody responses at 1 month after the third injection were dose dependent in recipients of vaccine without adjuvant or with MF59 but were similar at both doses when alum was the adjuvant. With the higher dose, the geometric means of serum ELISA antibody titers (95% confidence intervals) to purified VLP 1 month after the third injection were as follows: 10240 (1499 to 69938) without adjuvant, 10240 (1114 to 94145) with MF59, and 2190 (838 to 5723) with alum. Responses of subjects within each group were similar. Neutralizing and ELISA antibody titers were highly correlated (Spearman correlation = .85), confirming that ELISA titers are valid proxies for neutralizing antibodies. Conclusions: The HPV16 L1 VLP vaccine is well tolerated and is highly immunogenic even without adjuvant, with the majority of the recipients achieving serum antibody titers that were approximately 40-fold higher than what is observed in natural infection.

Original languageEnglish (US)
Pages (from-to)284-292
Number of pages9
JournalJournal of the National Cancer Institute
Volume93
Issue number4
DOIs
StatePublished - Feb 21 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine'. Together they form a unique fingerprint.

  • Cite this

    Harro, C. D., Pang, Y. Y. S., Roden, R. B. S., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., Dillner, J., Schiller, J. T., & Lowy, D. R. (2001). Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. Journal of the National Cancer Institute, 93(4), 284-292. https://doi.org/10.1093/jnci/93.4.284